KonstantinHristovDragnevMD

Clinical Trials

• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Start of enrollment: 2000 Mar 01

  Completed

  Phase 1

• Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer Start of enrollment: 2005 Aug 01

  Completed

  Phase 2

• Study of Tarceva and Targretin in Stage I-II Lung Cancer Start of enrollment: 2005 Dec 01

  Completed

  Not Applicable

• A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer Start of enrollment: 2009 Mar 01

  Completed

  Not Applicable

• Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer Start of enrollment: 2004 Sep 01

  Terminated

  Phase 1, Phase 2

• Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract Start of enrollment: 2003 Apr 01

  Completed

  Phase 1

• A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01

  Completed

  Phase 1, Phase 2

• A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01

  Completed

  Phase 2

• A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03

  Active, not recruiting

  Phase 3

• Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery Start of enrollment: 2014 Sep 01

  Terminated

  Phase 2

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) Start of enrollment: 2015 Jun 26

  Completed

  Phase 1, Phase 2

• A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Start of enrollment: 2016 May 11

  Completed

  Phase 2

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2017 Mar 24

  Active, not recruiting

  Phase 2

• Join now to see all